Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash from Financing Activities (2016 - 2022)

Historic Cash from Financing Activities for RedHill Biopharma (RDHL) over the last 11 years, with Q2 2022 value amounting to $14.9 million.

  • RedHill Biopharma's Cash from Financing Activities rose 94324.48% to $14.9 million in Q2 2022 from the same period last year, while for Jun 2022 it was $26.5 million, marking a year-over-year decrease of 6542.99%. This contributed to the annual value of $8.4 million for FY2024, which is 6073.98% down from last year.
  • As of Q2 2022, RedHill Biopharma's Cash from Financing Activities stood at $14.9 million, which was up 94324.48% from -$4.9 million recorded in Q1 2022.
  • In the past 5 years, RedHill Biopharma's Cash from Financing Activities ranged from a high of $59.1 million in Q1 2020 and a low of -$4.9 million during Q1 2022
  • In the last 5 years, RedHill Biopharma's Cash from Financing Activities had a median value of $7.9 million in 2020 and averaged $14.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 7840666.67% in 2018, then plummeted by 13240.52% in 2021.
  • RedHill Biopharma's Cash from Financing Activities (Quarter) stood at $18.4 million in 2018, then surged by 96.67% to $36.1 million in 2019, then tumbled by 78.0% to $7.9 million in 2020, then skyrocketed by 121.25% to $17.6 million in 2021, then fell by 15.11% to $14.9 million in 2022.
  • Its Cash from Financing Activities stands at $14.9 million for Q2 2022, versus -$4.9 million for Q1 2022 and $17.6 million for Q4 2021.